SkinBioTherapeutics Plc (SBTX.L) Research

SkinBioTherapeutics Plc is a life sciences enterprise dedicated to enhancing human health through the exploration and development of technologies that harness the power of the human microbiome. The company has developed two primary technological platforms: SkinBiotix: This innovative solution is designed to strengthen the skin's natural barrier, offer protection against infections, and promote the repair of damaged skin. AxisBiotix: Focusing on the intricate link between gut health and skin conditions, this technology aims to mitigate the symptoms experienced by individuals with psoriasis. SkinBioTherapeutics serves a wide range of industries, including cosmetic and pharmaceutical skincare, nutritional supplements, and infection control. The company maintains active collaborations with key partners: Croda Plc; the University of Manchester, for the creation of microbiome formulations that bolster the immune system; and Winclove Probiotics B.V., with whom it's developing a unique probiotic blend derived from specific bacterial species known to influence psoriasis pathways. Originally founded in 2015 as Skinbiotix Ltd, the company adopted its current name, SkinBioTherapeutics plc, in December 2016. Its operations are headquartered in Newcastle upon Tyne, United Kingdom.

Open SkinBioTherapeutics Plc (SBTX.L) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.